IL310938A - Anti-CCR8 antibodies and their uses - Google Patents

Anti-CCR8 antibodies and their uses

Info

Publication number
IL310938A
IL310938A IL310938A IL31093824A IL310938A IL 310938 A IL310938 A IL 310938A IL 310938 A IL310938 A IL 310938A IL 31093824 A IL31093824 A IL 31093824A IL 310938 A IL310938 A IL 310938A
Authority
IL
Israel
Prior art keywords
seq
antigen
chain variable
variable region
polypeptide sequence
Prior art date
Application number
IL310938A
Other languages
English (en)
Hebrew (he)
Original Assignee
Hifibio Hk Ltd
Hifibio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hifibio Hk Ltd, Hifibio Inc filed Critical Hifibio Hk Ltd
Publication of IL310938A publication Critical patent/IL310938A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL310938A 2021-08-20 2022-08-19 Anti-CCR8 antibodies and their uses IL310938A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021113913 2021-08-20
PCT/CN2022/113739 WO2023020621A1 (en) 2021-08-20 2022-08-19 Anti-ccr8 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
IL310938A true IL310938A (en) 2024-04-01

Family

ID=85239303

Family Applications (1)

Application Number Title Priority Date Filing Date
IL310938A IL310938A (en) 2021-08-20 2022-08-19 Anti-CCR8 antibodies and their uses

Country Status (10)

Country Link
US (1) US20250019451A1 (https=)
EP (1) EP4388009A4 (https=)
JP (1) JP2024531409A (https=)
KR (1) KR20240046533A (https=)
CN (1) CN118176210A (https=)
AU (1) AU2022331786A1 (https=)
CA (1) CA3225986A1 (https=)
IL (1) IL310938A (https=)
MX (1) MX2024002238A (https=)
WO (1) WO2023020621A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
WO2024040216A2 (en) 2022-08-19 2024-02-22 Fibrogen, Inc. Anti-ccr8 antibodies and uses thereof
JP2025534340A (ja) * 2022-10-02 2025-10-15 アールイーエムディー バイオセラピューティクス，インコーポレイテッド Ｃ－ｃケモカイン受容体タイプ８（ｃｃｒ８）アンタゴニスト抗体
JPWO2024248037A1 (https=) 2023-05-30 2024-12-05
WO2024255753A1 (zh) * 2023-06-12 2024-12-19 南京蓬勃生物科技有限公司 结合人ccr8的抗体及其用途
WO2025011439A1 (zh) * 2023-07-07 2025-01-16 齐鲁制药有限公司 一种抗人ccr8的单克隆抗体药物制剂及其用途
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof
CN119371535B (zh) * 2024-09-20 2025-07-11 百济神州(上海)生物科技有限公司 抗ccr8抗体及其用途
CN119841954B (zh) * 2025-03-12 2025-11-04 上海百英生物科技股份有限公司 一种抗人ccr8单克隆抗体及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044756A2 (en) * 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
WO2020138489A1 (ja) * 2018-12-27 2020-07-02 塩野義製薬株式会社 新規抗ｃｃｒ８抗体
CA3160204A1 (en) * 2020-01-06 2021-07-15 Vaccinex, Inc. Anti-ccr8 antibodies and uses thereof
TWI890283B (zh) * 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
TW202216771A (zh) * 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體

Also Published As

Publication number Publication date
CN118176210A (zh) 2024-06-11
JP2024531409A (ja) 2024-08-29
WO2023020621A1 (en) 2023-02-23
EP4388009A1 (en) 2024-06-26
EP4388009A4 (en) 2025-07-09
US20250019451A1 (en) 2025-01-16
KR20240046533A (ko) 2024-04-09
CA3225986A1 (en) 2023-02-23
AU2022331786A1 (en) 2024-04-04
MX2024002238A (es) 2024-04-29

Similar Documents

Publication Publication Date Title
IL310938A (en) Anti-CCR8 antibodies and their uses
JP2024531409A5 (https=)
CN106967172B (zh) 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
KR102469286B1 (ko) 항-pd1 단일클론 항체, 이의 약제학적 조성물 및 이의 용도
JP2021514664A5 (https=)
IL276830B1 (en) Anti-claudin 18.2 antibodies and their uses
JP2021528047A5 (https=)
JP2021517459A5 (https=)
WO2023016348A1 (en) Cldn18.2-targeting antibody, bispecific antibody and use thereof
CA3207494A1 (en) Hhla2 binding agents with novel activity
JP2023525991A5 (https=)
US10626183B2 (en) IFN-γ-inducible regulatory T cell convertible anti-cancer (IRTCA) antibody and uses thereof
CN117257934A (zh) 药物组合物及其用途
US11767368B1 (en) Antigen-binding protein and use thereof
WO2022166700A1 (zh) 基于ccdc112抑制肿瘤细胞生长的方法
CN109053888B (zh) 一种抗人csf-1r单克隆抗体及其用途
CN115505041B (en) Anti-EphA 2 antibodies and uses thereof
CN120040594B (zh) 一种靶向flt3基因编辑通用型car-t细胞的制备方法和应用
WO2024131846A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
NZ783695A (en) Binding molecule specific for cd73 and use of binding molecule
NZ766836B2 (en) Anti-claudin 18.2 antibodies and uses thereof
KR20250004624A (ko) T 세포 및 nk 세포 인게이저
NZ766968A (en) Anti-cd73 antibodies and uses thereof
NZ766968B2 (en) Anti-cd73 antibodies and uses thereof
WO2023222027A1 (zh) 一种抗trop-2/cd3双特异性抗体